Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

7/5/24 10:32:48 AM ET

Medical Specialities

Health Care

Get the next $GH alert in real time by email

SC 13G/A 1 Guardant2806024.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Guardant Health, Inc. (Amendment No.1) ----------------------------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------------------------- (Title of Class of Securities) 40131M109 ----------------------------------------------------------------------- (CUSIP Number) 28 June 2024 ----------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No. 40131M109 _______________________________________________________________________ 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Baillie Gifford & Co (Scottish partnership) _______________________________________________________________________ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a).................................................................... (b).................................................................... _______________________________________________________________________ 3. SEC Use Only _______________________________________________________________________ 4. Citizenship or Place of Organization SCOTLAND UK _______________________________________________________________________ Number of 5. Sole Voting Power 6,027,818 Shares Bene ______________________________________________________ ficially by 6. Shared Voting Power 0 Owned by Each ______________________________________________________ Reporting 7. Sole Dispositive Power 6,093,286 Person With: ______________________________________________________ 8. Shared Dispositive Power 0 _______________________________________________________________________ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 6,093,286 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 4.98% _______________________________________________________________________ 12. Type of Reporting Person (See Instructions) IA _______________________________________________________________________ Item 1. (a) Name of Issuer Guardant Health, Inc. (b) Address of Issuers Principal Executive Offices 3100 Hanover Street, Palo Alto, CA 94304 Item 2. (a) Name of Person Filing Baillie Gifford & Co (b) Address of Principal Business Office or, if none, Residence Calton Square 1 Greenside Row Edinburgh EH1 3AN Scotland UK (c) Citizenship Scotland UK (d) Title of Class of Securities Common Stock (e) CUSIP Number 40131M109 Item 3. If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) An investment adviser in accordance with rule 240.13d- 1(b)(1)(ii)(E) (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F) (g) A parent holding company or control person in accordance with rule 240.13d-1(b) (1)(ii)(G) (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813) (j) X A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ Item 4. Ownership. Provide the following information regarding the aggregate number and Percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: see row (9) on page 2. (b) Percent of Class: see row (11) on page 2. (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote See row (5) on page 2. (ii) Shared power to vote or to direct the vote See row (6) on page 2 (iii) Sole power to dispose or to direct the disposition of See row (7) on page 2 (iv) Shared power to dispose or to direct the disposition of See row (8) on page 2 Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [ X ] Item 6. Ownership of More than Five Percent on Behalf of Another Person. Securities reported on this Schedule 13G as being beneficially owned by Baillie Gifford & Co. are held by Baillie Gifford & Co. and/or one or more of its investment adviser subsidiaries, which may include Baillie Gifford Overseas Limited, on behalf of investment advisory clients, which may include investment companies registered under the Investment Company Act, employee benefit plans, pension funds or other institutional clients. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief: - the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. - the foreign regulatory scheme applicable to investment advisers is substantially comparable to the functionally equivalent U.S. institution(s). I also undertake to furnish the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D. SIGNATURE After reasonable enquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct 05 July 2024 ________________________________ Date Grant Meikle _______________________________________ Signature Grant Meikle Compliance Manager _______________________________________ Name/Title The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representatives authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule,including all exhibits. See rule 240.13d- 7 for other parties for whom copies are to be sent. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

Get the next $GH alert in real time by email

Date	Price Target	Rating	Analyst
6/28/2024	$36.00	Neutral → Buy	Guggenheim
6/3/2024	$32.00	Buy	Jefferies
4/24/2024	$28.00	Buy	Craig Hallum
12/14/2023		Neutral	Guggenheim
12/13/2023		Peer Perform	Wolfe Research
11/13/2023	$27.00	Mkt Perform → Outperform	Raymond James
9/28/2023	$34.00	Outperform	Bernstein
9/27/2023	$40.00	Neutral → Overweight	Piper Sandler

Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

Chat with this insight

Recent Analyst Ratings for $GH

$GH Financials

Live finance-specific insights

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Guardant Health's Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening

$GH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guardant Health upgraded by Guggenheim with a new price target

Jefferies resumed coverage on Guardant Health with a new price target

Craig Hallum resumed coverage on Guardant Health with a new price target

$GH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Mignone Roberto claimed no ownership of stock in the company (SEC Form 3)

Director Tariq Musa converted options into 250 shares, increasing direct ownership by 6% to 4,746 units (SEC Form 4)

Director Potter Myrtle S converted options into 69 shares, increasing direct ownership by 0.51% to 13,585 units (SEC Form 4)

$GH Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

SEC Form SC 13G filed by Guardant Health Inc.

SEC Form SC 13G/A filed by Guardant Health Inc. (Amendment)

$GH SEC Filings

SEC Form 8-K filed by Guardant Health Inc.

SEC Form 8-K filed by Guardant Health Inc.

SEC Form 424B5 filed by Guardant Health Inc.

$GH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

$GH Press Releases

Fastest customizable press release news feed in the world

$GH Market Insights

Live Market Insights

$GH Leadership Updates

Live Leadership Updates

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health Named to TIME's List of the Best Inventions of 2024

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024

Guardant Health Launches Enhanced Guardant360 Test On Guardant Infinity Platform; New Test Covers 10 Times More Genes And Quantifies Tumor Burden With 10 Times Higher Sensitivity; Medicare And Major Private Payers Cover Test For Comprehensive Genomic Profiling Of Advanced Solid Tumors

Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast

B of A Securities Maintains Buy on Guardant Health, Raises Price Target to $40

Roberto A. Mignone Joins Guardant Health Board of Directors

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer

$GH FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

July 30, 2024 - FDA Roundup: July 30, 2024

May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

Recent Analyst Ratings for
$GH

$GH
Financials

$GH
Analyst Ratings

$GH
Insider Trading

$GH
Large Ownership Changes

$GH
SEC Filings

$GH
Insider Purchases

$GH
Press Releases

$GH
Market Insights

$GH
Leadership Updates

$GH
FDA approvals